LY317615

· Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for LY317615, covering 2007-01-26 to 2020-08-10. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas. [Phase 2]